Combretastatin A4

Catalog No.S7783

Combretastatin A4 Chemical Structure

Molecular Weight(MW): 316.35

Combretastatin A4 is a microtubule-targeting agent that binds β-tubulin with Kd of 0.4 μM.Phase 3.

Size Price Stock Quantity  
USD 97 In stock
USD 397 In stock
USD 997 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Purity & Quality Control

Choose Selective Microtubule Associated Inhibitors

Biological Activity

Description Combretastatin A4 is a microtubule-targeting agent that binds β-tubulin with Kd of 0.4 μM.Phase 3.
Targets
β-tubulin [1]
0.4 μM(Kd)
In vitro

Combretastatin A4 inhibits the growth of MDA-MB-231, A549, Hela, HL-60, SF295, HCT-8, MDA-MB435, PC3M, OVCAR-8, NCI-H358M, and lymphocyte cells with IC50 of 2.8, 3.8, 0.9, 2.1, 6.2, 5.3, 7.9, 4.7, 0.37, 8, and 3.2 nM, respectively.[1] [2] 1 μM Combretastatin A4 inhibits tubulin polymerization by 35%, and 10 μM nearly completely blocks tubulin polymerization. Combretastatin A4 demonstrates great relative binding capacity, reaching 78% of colchicine binding.[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SKMEL-5 MYnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Ml3RR5l1d3SxeHnjJINwdmOnboTyZZRqd25icnXxeYlz\WRidH:gbY5pcWKrdDC1NEUh[2WubDDndo94fGhiaX6gV2tOTUxvNTDt[Yxidm:vYTDj[YxtKGyrbnXzMEBGTDVyPUOuNFBGNTB6IN88US=> NGDh[osyQDd3M{Ww
A-549 MVrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MX3DfZRwfG:6aXOgZ49v[2WwdILheIlwdiC{ZYH1bZJm\CC2bzDpcohq[mm2IEWwKUBk\WyuIHfyc5d1cCCrbjDBMVU1QSCudX7nJINiemOrbn;tZUBk\WyuIHzpcoV{NCCHREWwQVEvOjCHLUC2JO69VQ>? NXvVcoxkOTh5NUO1NC=>
MCF-7 MWTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MVnDfZRwfG:6aXOgZ49v[2WwdILheIlwdiC{ZYH1bZJm\CC2bzDpcohq[mm2IEWwKUBk\WyuIHfyc5d1cCCrbjDNR2YuPyCkcnXhd5Qh[2G{Y3nuc41iKGOnbHygcIlv\XNuIFXEOVA:Oy56MFWtNFYh|ryP M4rZdFE5PzV|NUC=
HT-29 NYDNcIdbT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MmTwR5l1d3SxeHnjJINwdmOnboTyZZRqd25icnXxeYlz\WRidH:gbY5pcWKrdDC1NEUh[2WubDDndo94fGhiaX6gTHQuOjliY3;sc44h[WSnbn;jZZJkcW6xbXGgZ4VtdCCuaX7ld{whTUR3ME2xMlIxTS1yNjFOwG0> NUT3N|U4OTh5NUO1NC=>
MLM melanoma cell M1y4[mdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NFzwdJVEgXSxdH;4bYMh[2:wY3XueJJifGmxbjDy[ZF2cXKnZDD0c{BqdmirYnn0JFUxLSClZXzsJIdzd3e2aDDpckBOVE1ibXXsZY5wdWFiY3XscEBtcW6nczygSWQ2OD1zLkSwSU0xPiEQvF2= MUmxPFc2OzVy
M14 NWXnTZFUS3m2b4TvfIlkcXS7IHHzd4F6 NITFXoZKdiC4aYTyc{BkgXSxdH;4bYMh[WO2aY\peJkhf2G|IITld5Rm\CCjZ3HpcpN1KGi3bXHuJI1mdGGwb33hJINidmOncjCoUVE1MSClZXzsJIxqdmVuIFfJOVA:OC5yMECxJO69VQ>? MX[xNlczQTZ2MB?=
SK-OV3 NUnM[FhwS3m2b4TvfIlkcXS7IHHzd4F6 NHL5d5RKdiC4aYTyc{BkgXSxdH;4bYMh[WO2aY\peJkhfGW|dHXkJIFo[Wmwc4SgbJVu[W5ib4\hdolidiClYX7j[ZIhMFONLV;WN{kh[2WubDDsbY5mNCCJSUWwQVAvODByMTFOwG0> MUixNlczQTZ2MB?=
HL60 cells MWTDfZRwfG:6aXPpeJkh[XO|YYm= M4ja[lczKGh? MmLWR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTGw3OCClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUCuNFAxOSEQvF2= MoX5NlA4OzF|NUW=
SK-OV-3 MlP5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M3rkV|Q5KGh? MmS4S5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gV2suV1ZvMzDh[pRmeiB2ODDodpMh[nliU2LCJIF{e2G7LDDHTVUxRTBwMECwNVMh|ryP MnvXNVg4OjJzMke=
HepG2 cells NHzQd5pEgXSxdH;4bYNqfHliYYPzZZk> MV7DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDI[ZBIOiClZXzsd{whUUN3ME2wMlAxODF2IN88US=> M1HUUlE4OTJ5ME[x
ZR-75-1 M1jq[2N6fG:2b4jpZ4l1gSCjc4PhfS=> NXTIOZdsS3m2b4TvfIlkcXS7IHHnZYlve3RiWmKtO|UuOSClZXzsJIxqdmVuIFnDOVA:OC5yMECyOEDPxE1? NXHP[4ZNOTd{NEm2OFk>
HeLa cell NYfZRmlQS3m2b4TvfIlkcXS7IHHzd4F6 MX\DfZRwfG:6aXPpeJkh[WejaX7zeEBJ\UyjIHPlcIwhdGmwZTygTWM2OD1yLkCwNFMh|ryP NI\iflQyPzJ2OU[0PS=>
HCT116 cell Mn7qR5l1d3SxeHnjbZR6KGG|c3H5 MVPDfZRwfG:6aXPpeJkh[WejaX7zeEBJS1RzMU[gZ4VtdCCuaX7lMEBKSzVyPUCuNFAxOzVizszN MWGxO|I1QTZ2OR?=
KBV1 cells MmfkR5l1d3SxeHnjbZR6KGG|c3H5 M1XDcVczKGh? M2TpR2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJJZqdmKuYYP0bY5mNXKnc3nzeIFvfCCNQm[xJINmdGy|IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:OC5yMEC0JO69VQ>? MkjwNlA4OzF|NUW=
SKOV3 M2P1O2N6fG:2b4jpZ4l1gSCjc4PhfS=> NV;RW5JVS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hW0uRVkOgZ4VtdHNiYomgV3JDKGG|c3H5MEBIUTVyPUCuNFAxPDJizszN MmnUNlQxOTZyMEK=
SKOV3 cells M4myXWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NHPaZYpIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBUU0:YMzDj[YxteyCkeTDzeYxnd3Kqb3ThcYlv\SCEIHHzd4F6NCCJSUWwQVAvODByNEKg{txO MnzpNlM4PzJ|MEm=
HeLa cells MXLDfZRwfG:6aXPpeJkh[XO|YYm= Mn;KR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTIVN[SClZXzsd{BjgSCPVGSgZZN{[XluIFnDOVA:OC5yMEC1NUDPxE1? NGq0bWMyQTh5OUe1PC=>
DU145 cells NET3W3VEgXSxdH;4bYNqfHliYYPzZZk> NX3U[3JtS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hTFVzNEWgZ4VtdHNiYomgV3JDKGG|c3H5MEBIUTVyPUCuNFAxPTRizszN NWLkToZ[OjRyMU[wNFI>
DU145 cells NIm1enpIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M3TFd2dzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGRWOTR3IHPlcIx{KGK7IIP1cIZwemixZHHtbY5mKEJiYYPzZZktKEeLNUC9NE4xODB3NDFOwG0> Mlm4NlM4PzJ|MEm=
SK-N-BE MVnQdo9tcW[ncnH0bY9vKGG|c3H5 MYi3NkBp M3rQSWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIlvKGi3bXHuJHNMNU5vQlWgZ4VtdHNiYYPz[ZN{\WRiYYOgZ4VtdCC4aXHibYxqfHliYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF0xNjByMEW4JO69VQ>? M2X4T|IzOzJ7NU[x
NCIH460 cells Mn\lR5l1d3SxeHnjbZR6KGG|c3H5 M4DXeVQ5KGh? NYLmUWtuS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVkOLSES2NEBk\WyuczDh[pRmeiB2ODDodpMh[nliU2LCJIF{e2G7LDDHTVUxRTBwMECwOkDPxE1? NW\pNHlKOTh|MEO4OFk>
KB-VIN10 cells M{fadXBzd2yrZnXyZZRqd25iYYPzZZk> NF7yVXk4OiCq NHL2doRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFvCMXZKVjFyIHPlcIx{KG:4ZYKt[ZhxemW|c3nu[{BRNWeyIEG3NE9OTFJzIHHmeIVzKDd{IHjyd{BjgSCvZYTofYxmdmViYnz1[UBie3OjeTygTWM2OD1yLkCwNFch|ryP NF\R[VMzOTZ2MUewNC=>
HCT116 cells MWDDfZRwfG:6aXPpeJkh[XO|YYm= NYXKS5RUPzJiaB?= Mo\sR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTGNVOTF4IHPlcIx{KGG|c3Xzd4VlKGG|IILl[JVkfGmxbjDv[kBcO0ifdHj5cYllcW6nIHnuZ49zeG:{YYTpc44h[W[2ZYKgO|IhcHK|IHL5JJNkcW62aXzsZZRqd25iY3;1cpRqdmduIFnDOVA:OC5yMEC3OEDPxE1? MUKyNVk2PTR3NB?=
DU145 cells Mn7RR5l1d3SxeHnjbZR6KGG|c3H5 MoSyOFghcA>? NX;3N5NmS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hTFVzNEWgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KFOUQjDhd5NigSxiR1m1NF0xNjByMEig{txO MlT2NVg{ODN6NEm=
RS4:11 cells MYfQdo9tcW[ncnH0bY9vKGG|c3H5 MVy3NkBp MWjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFKVNEqxNUBk\WyuczDh[pRmeiB5MjDodpMh[nliKEOtLFQtPS2maX3leIh6dHSqaXH6c4wuOi27bDmtNkw2NWSrcHjlcpltfGW2cnH6c4xqfW1iYoLvcYll\SC2ZYP0MEBKSzVyPUCuNFAxQCEQvF2= Mnm4NlU4QDV4MEW=
HCT 116 M1PxVWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MYLDc45k\W62cnH0bY9vKHeqaXPoJJBzd2S3Y3XzJFUxLSCrbnjpZol1cW:wIH;mJIdzd3e2aDDv[kBpfW2jbjDjc4xwdiC2dX3vdkBJS1RiMUG2MEBKSzVyPUCuNFAxQSEQvF2= NH;zXmQyOTdzNE[xNy=>
HeLa cells M4nZU2N6fG:2b4jpZ4l1gSCjc4PhfS=> MkXrO|IhcA>? MYLDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDI[WxiKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDy[ZNignW{aX6gZoF{\WRiZnz1c5Jme2OnbnPlJIF{e2G7LDDJR|UxRTBwMECwPUDPxE1? NXvJXJFFOjR4Nkm4PFg>
BNL 1ME A.7R.1 cells NIXZRWZEgXSxdH;4bYNqfHliYYPzZZk> NYPIWlJ5S3m2b4TvfIlkcXS7IHHnZYlve3RibX;1d4UhSk6OIEHNSUBCNjeULkGgZ4VtdHNuIFnDOVA:OC5yMEC5JO69VQ>? MXKyOVc5PTZyNR?=
Calu6 NE[zNVRRem:uaX\ldoF1cW:wIHHzd4F6 MYK0PEBp MmjwRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCFYXz1OkBi\nSncjC0PEBpenNiYomgd5Bm[3S{b4Doc5RwdWW2comsJGlEPTB;MD6wNFA6PCEQvF2= MVyyNVc4PDR7OR?=
melanoma B16 cell NWX0S|ZUT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MUPDc45k\W62cnH0bY9vKHeqaXPoJJBzd2S3Y3XzJFUxLSCrbnjpZol1cW:wIH;mJIdzd3e2aDDv[kBufXKrbnWgcYVt[W6xbXGgRlE3KGOnbHygcIlv\SxiSVO1NF0xNjByMTFOwG0> NE\EbVUyOTdzNE[xNy=>
DU145 cells NX71dY8yS3m2b4TvfIlkcXS7IHHzd4F6 M{naRWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGRWOTR3IHPlcIx{KGK7IGPSRkBie3OjeTygS2k2OD1yLkCwNUDPxE1? MV2yNFQ6Pjl{Mx?=
HCT116 cells NVXuT|NEWHKxbHnm[ZJifGmxbjDhd5NigQ>? M4XqPFczKGh? NEXqT2NCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjDWFEyPiClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRUKGG|c3H5MEBKSzVyPUCuNFAyKM7:TR?= M3r2eVIyOTF{MUOw
HCT15 cells MnPPVJJwdGmoZYLheIlwdiCjc4PhfS=> MVm3NkBp NUfZXol1SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIR3QyPSClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRUKGG|c3H5MEBKSzVyPUCuNFAyKM7:TR?= M3TYOlIyOTF{MUOw
HL60 cells MWnQdo9tcW[ncnH0bY9vKGG|c3H5 M1\DOlczKGh? M{\KcGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFy2NEBk\WyuczDhd5Nme3OnZDDhd{Boem:5dHigbY5pcWKrdHnvckBi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUCuNFAyKM7:TR?= Mmf1NlE3PjN|MUm=
A10 cells M1jpNGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Mm\uOFghcA>? NEXnNZhIem:5dHigbY5pcWKrdHnvckBw\iC{YYSgRVExKGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MD6wNFEh|ryP NGnPS3IzOjB2NEG2OC=>
HUVEC cells NV;KbHEyT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M1HxW|Q5KGh? MVfHdo94fGhiaX7obYJqfGmxbjDv[kBJXV[HQzDj[YxteyCjZoTldkA1QCCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVAvODBzIN88US=> M3z5VlIzODR2MU[0
HL60 cells M3jwXGN6fG:2b4jpZ4l1gSCjc4PhfS=> MVq3NkBp M2jWN2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhNPjBiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME2wMlAxOSEQvF2= MoHhNlIyOzZ|MUK=
HL60 cells MnrmVJJwdGmoZYLheIlwdiCjc4PhfS=> NIrrV5M4OiCq M3OwbWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFy2NEBk\WyuczDhd5Nme3OnZDDhd{Boem:5dHigbY5pcWKrdHnvckBi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUCuNFAyKM7:TR?= M3fZR|IzPTd6MUGx
NCI-H522 cells Ml21S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M3LXPVQ5KGh? M2HDSmdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KNUKyJINmdGy|IHHmeIVzKDR6IHjyd{BjgSCVUlKgZZN{[XluIFfJOVA:OC5yMEGg{txO M3jPeFIzQTh{MUKy
MDA-MB-435 cells MnXPS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MWm0PEBp M3X6VWdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG1FSS2PQj20N|Uh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IGPSRkBie3OjeTygS2k2OD1yLkCwNUDPxE1? NWPzfVVwOjJ7OEKxNlI>
OVCAR3 MUPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NVL3c2ZCPDhiaB?= MmPDS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gU3ZESVJ|IHPlcIx{KGGodHXyJFQ5KGi{czDifUBUWkJiYYPzZZktKEeLNUC9NE4xODFizszN NYPrNog4OjJ7OEKxNlI>
NCI/ADR-RES cells M3;yTmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MX20PEBp NUjWRmtTT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLL1HEVk1TTVNiY3XscJMh[W[2ZYKgOFghcHK|IHL5JHNTSiCjc4PhfUwhT0l3ME2wMlAxOSEQvF2= M371blIzQTh{MUKy
PC3 cells MYHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NGnpeZI1QCCq MorUS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gVGM{KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDTVmIh[XO|YYmsJGdKPTB;MD6wNFEh|ryP NXfMfHNUOjJ7OEKxNlI>
DU145 cells NIDIbFVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NFS4epE1QCCq M1n1Umdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGRWOTR3IHPlcIx{KGGodHXyJFQ5KGi{czDifUBUWkJiYYPzZZktKEeLNUC9NE4xODFizszN M2PIR|IzQTh{MUKy
MDA-MB-231 cells NGrQSHBIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M1XvXFQ5KGh? NELkVHRIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBOTEFvTVKtNlMyKGOnbHzzJIFnfGW{IES4JIhzeyCkeTDTVmIh[XO|YYmsJGdKPTB;MD6wNFEh|ryP NFvHNXozOjl6MkGyNi=>
CEM cells M4XhfmN6fG:2b4jpZ4l1gSCjc4PhfS=> NGTyW404OiCq NYD6XnZ1S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hS0WPIHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9NE4xODFizszN M1zNXlIzPjd4MkS3
HCT116 cells MnPwR5l1d3SxeHnjbZR6KGG|c3H5 NEXWUlc4OiCq MkXXR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTGNVOTF4IHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9NE4xODFizszN M1S4PFIzPjd4MkS3
MDA-MB-435 cells Mm[5R5l1d3SxeHnjbZR6KGG|c3H5 MUm3NkBp M{jqWmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1FSS2PQj20N|Uh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1yLkCwNUDPxE1? NXL4S5RDOjJ4N{[yOFc>
HaCaT cells NHrYc4FRem:uaX\ldoF1cW:wIHHzd4F6 NXvqRoNYSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIZWNiXCClZXzsd{Bie3Onc4Pl[EBieyClZXzsJJZq[WKrbHn0fUBjgSCPVGSgZZN{[XluIFnDOVA:OC5yMEGg{txO MUWyN|A3OzRyMR?=
HL60 cells MnHrVJJwdGmoZYLheIlwdiCjc4PhfS=> NIHnOXE4OiCq M{jpcWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFy2NEBk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR|UxRTBwMECxJO69VQ>? NGnPW2IzOzFzN{G3NS=>
HL60 cells NUPoe5ZbWHKxbHnm[ZJifGmxbjDhd5NigQ>? MXm3NkBp NW\jZnVMSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIUFYxKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTCoN{0pPCx3LXTpcYV1cHmudHjpZZpwdC1{LYnsLU0zNDVvZHnwbIVvgWy2ZYTyZZpwdGm3bTDido9ucWSnIITld5QtKEmFNUC9NE4xODFizszN Ml7KNlU4QDV4MEW=
HT-29 MVXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MnHJS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gTHQuOjliY3XscJMh[nliTWTUJIF{e2G7LDDJR|UxRTBwMECxJO69VQ>? NIq2ZXMzPTZ6OUGxNS=>
HL60 cells Mme4VJJwdGmoZYLheIlwdiCjc4PhfS=> NXn4dYdwPzJiaB?= M2KxUGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFy2NEBk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR|UxRTBwMECxJO69VQ>? MmLNNlA1OjB2M{m=
Hs578T cells NWXwcHZOT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MWG0PEBp MXfHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDId|U4QFRiY3XscJMh[W[2ZYKgOFghcHK|IHL5JHNTSiCjc4PhfUwhT0l3ME2wMlAxOSEQvF2= NVvoZZQ6OjJ7OEKxNlI>
HL60 cells M1ryUmN6fG:2b4jpZ4l1gSCjc4PhfS=> NXH3OHI6PzJiaB?= MWjDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIUFYxKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MD6wNFEh|ryP Mn:zNlM1PDV2OU[=
SKOV3 cells M{m1Rmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NG\rb4RIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBUU0:YMzDj[YxteyCkeTDNWHQh[XO|YYmsJGlEPTB;MD6wNFEh|ryP NFf5V44zPTZ6OUGxNS=>
MDA-MB-468 cells Mk\QR5l1d3SxeHnjbZR6KGG|c3H5 NIfyRo41KGSjeYO= MWLDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvNE[4JINmdGy|IHHzd4V{e2WmIHHzJINmdGxidnnhZoltcXS7IHHmeIVzKDRiZHH5d{BjgSCPVGOgZZN{[XluIFnDOVA:OC5yMEGxJO69VQ>? MlSwNlQzOTB3MEO=
MCF7 cells NVrrWW1xWHKxbHnm[ZJifGmxbjDhd5NigQ>? Mo\XO|IhcA>? NX\ycmZvSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkhcW5iaIXtZY4hVUOINzDj[YxteyCjc4Pld5Nm\CCjczDj[YxtKH[rYXLpcIl1gSCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVAvODBzMUGg{txO NWPwcoFZOjJ|Mkm1OlE>
H460 NIj0cGNEgXSxdH;4bYNqfHliYYPzZZk> MWnDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIOFYxKGOnbHzzJIJ6KHO3bH\vdohw\GGvaX7lJGIhfGW|dDygTWM2OD1yLkCwNVIh|ryP NGPPeFYyQDd6M{KwOy=>
H460 NGrnZWVRem:uaX\ldoF1cW:wIHHzd4F6 NETrboFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFi0OlAh[2WubIOsJGlEPTB;MD6wNFEzPCEQvF2= MnjONVY4OjJ4M{O=
NCI-H460 cells NFTKcJpEgXSxdH;4bYNqfHliYYPzZZk> MkOyO|IhcA>? NUjHXnB6S3m2b4TvfIlkKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gUmNKNUh2NkCgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KHO3bH\vdohw\GGvaX7lJGIhfGW|dDygTWM2OD1yLkCwNVMh|ryP NXG4d4V5OTh|OU[4OVc>
OVCAR8 cells MXPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MnezPVYhcA>? MorYS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gU3ZESVJ6IHPlcIx{KG:4ZYLlfJBz\XO|aX7nJHAu\2y7Y3;wdo91\WmwIHHmeIVzKDl4IHjyd{whUUN3ME2wMlAxOTNizszN MVOyNlA1PDF4NB?=
NCI/ADR-RES cells NXjNN41yS3m2b4TvfIlkcXS7IHHzd4F6 MVzDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDOR2kwSUSULWLFV{Bk\WyuczDhd5Nme3OnZDDhd{Boem:5dHigbY5pcWKrdHnvckBjgSC2conwZY4h[my3ZTDlfINtfXOrb36gZZN{[XluIFnDOVA:OC5yMEGzJO69VQ>? NUS0emdqOjN{MUS0OVI>
OVCAR8 cells M2ixRmN6fG:2b4jpZ4l1gSCjc4PhfS=> NUnyOlN5QTZiaB?= M3j0eWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG9XS0GUODDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB7NjDodpMh[nliR3nlcZNiKHO2YXnubY5oNWKjc3XkJIxq\2i2IH3pZ5Jwe2OxcImsJGlEPTB;MD6wNFE{KM7:TR?= M{e0UVI2ODJ3OUmx
NCI/ADR-RES cells MYHDfZRwfG:6aXPpeJkh[XO|YYm= NX\ZfpBYQTZiaB?= M{foW2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG5EUS:DRGKtVmVUKGOnbHzzJIF{e2W|c3XkJIF{KGe{b4f0bEBqdmirYnn0bY9vKGGodHXyJFk3KGi{czDifUBIcWWvc3Ggd5RicW6rbnetZoF{\WRibHnnbJQhdWmlcn;zZ49xgSxiSVO1NF0xNjByMUOg{txO NHzQNWczPTB{NUm5NS=>
OVCAR8 cells MkHsR5l1d3SxeHnjbZR6KGG|c3H5 NHHTfWZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBQXkODUkigZ4VtdHNiYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36gZpkhfHK7cHHuJIJtfWViZYjjcJV{cW:wIHHzd4F6NCCLQ{WwQVAvODBzMzFOwG0> M{D2N|I{OjF2NEWy
HuTu 80 cells NGrDRmxRem:uaX\ldoF1cW:wIHHzd4F6 NVjSdHpEPzJiaB?= NELwR|FCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBqdiCqdX3hckBJfVS3IEiwJINmdGy|IHHzd4V{e2WmIHHzJINmdGxidnnhZoltcXS7IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:OC5yMEGzO{DPxE1? MYeyNlMzQTV4MR?=
K562 cells NVXYbnJCS3m2b4TvfIlkcXS7IHHzd4F6 M1O1WmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGs2PjJiY3XscJMtKEmFNUC9NE4xODF2IN88US=> M4nveFE6QDN5NUm0
NCI/ADR (MDR) cells MXPGeY5kfGmxbjDhd5NigQ>? MUfD[YxtKGO7Y3zlJIFzemW|dDDpckBPS0lxQVTSJEhOTFJrIHPlcIx{KGK7IHHjZ5VufWyjdHnvckBifCCJMj;NJJBp[XOnLDDJR|UxRTBwMECxOUDPxE1? NI\wSWIyPjN5N{G4Oy=>
HUVEC MYPQdo9tcW[ncnH0bY9vKGG|c3H5 NHrS[mlCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjVWmVENCCLQ{WwQVAvODBzNTFOwG0> MVOxOlczOjZ|Mx?=
KB cell MmLJVJJwdGmoZYLheIlwdiCjc4PhfS=> NHSzR21CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFvCJINmdGxibHnu[UBjgSCvZYTofYxmdmViYnz1[UBlgWViYYPzZZktKEmFNUC9NE4xODF3IN88US=> MXmxO|A{PDF2Nx?=
KB-VIN10 cell NEfOO4tRem:uaX\ldoF1cW:wIHHzd4F6 NX7UV5ZzSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDLRk1XUU5zMDDj[YxtKGyrbnWgZpkhdWW2aIns[Y5mKGKudXWg[JlmKGG|c3H5MEBKSzVyPUCuNFAyPSEQvF2= MYSxO|A{PDF2Nx?=
Human SH-SY5Y neuroblastoma cells MnnwSpVv[3Srb36gZZN{[Xl? MV;Jcohq[mm2b4L5JINwdmOnboTyZZRqd25iYXfhbY5{fCCKdX3hckBUUC2VWUXZJI5mfXKxYnzhd5RwdWFiY3XscJMtKEmFNUC9NE4xODF3IN88US=> Ml7oNVU6PjN5MkK=
SW620 cells NWPRNZZpWHKxbHnm[ZJifGmxbjDhd5NigQ>? NGrnPYY4OiCq MljzRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgbY4hcHWvYX6gV3c3OjBiY3XscJMh[XO|ZYPz[YQh[XNiY3XscEB3cWGkaXzpeJkh[W[2ZYKgO|IhcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME2wMlAxOTV{IN88US=> MmHvNlI{Ojl3NkG=
Molt4/C8 cells M3fy[3Bzd2yrZnXyZZRqd25iYYPzZZk> MVrBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2xbIS0M2M5KGOnbHzzMEBKSzVyPUCuNFAyPiEQvF2= Mn;jNVcxOzRzNUC=
ACHN cell MoDlVJJwdGmoZYLheIlwdiCjc4PhfS=> NV[3bJR3SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBlenWpIILld4l{fGGwdDDBR2hPKGOnbHygcIlv\SCneIDy[ZN{cW6pIF3EVlEh[nliQXzhcYFzKEKudXWgZZN{[XluIFnDOVA:OC5yMEG2JO69VQ>? MmXHNVczQDZ|OUO=
Molt4/C8 cells NVXOeGhiWHKxbHnm[ZJifGmxbjDhd5NigQ>? MUOzJIRigXN? NYrXSYlmSW62aYDyc4xq\mW{YYTpeoUh\W[oZXP0JIFo[Wmwc4SgbJVu[W5iTX;seFQwSzhiY3XscJMh[W[2ZYKgN{Bl[Xm|LDDJR|UxRTBwMECxOkDPxE1? Mnr4NVc1OTl4MEe=

... Click to View More Cell Line Experimental Data

In vivo In NT2 and MDA-MB-231 mammary tumor model, administration of Combretastatin A4 (100 mg/kg, i.p.) induces a significant decrease in lipids R1 and a reduction in tumor pO2 measured by electron paramagnetic resonance (EPR) oximetry.[2] Combretastatin A4 (100 mg/kg, i.p.) significant decreases the Ktrans in male NMRI mice.[3]

Protocol

Kinase Assay:[1]
- Collapse

Competitive binding assay using LC-MS/MS:

Colchicine (1.2 μ M) is incubated with tubulin (1.3 mg/mL) in the incubation buffer (80 mM PIPES, 2.0 mM MgCl2, 0.5 mM EGTA, pH 6.9) at 37℃ for 1 h. Varying concentrations (0.1 − 125 μ M) of Combretastatin A4 are used to compete with colchicine originally bound to tubulin. After incubation, the filtrate is obtained. The ability of the analogue to inhibit the binding of colchicine is expressed as a percentage of control binding in the absence of any competitor.
Cell Research:[1]
- Collapse
  • Cell lines: MDA-MB-231, A549, and Hela cells
  • Concentrations: ~3.8 nM
  • Incubation Time: 72 h
  • Method: MDA-MB-231, A549, and HeLa cells are grown in DMEM medium (115 units/mL of penicillin G, 115 μg/mL of streptomycin, and 10% fetal bovine serum). Cells are seeded in 96-well plates (5000 cells/well) containing 50 μL of growth medium for 24 h. After medium removal, 100 μL of fresh medium containing individual analogue compounds at different concentrations is added to each well and incubated at 37 ℃ for 72 h. After 24 h of culture, the cells are supplemented with 50 μL of analogue compounds dissolved in DMSO (less than 0.25% in each preparation). After 72 h of incubation, 20 μL of resazurin is added for 2 h before recording fluorescence at 560 nm (excitation) and 590 nm (emission) using a Victor microtiter plate fluorimeter. The IC50 is defined as the compound concentration required to inhibit cell proliferation by 50% in comparison with cells treated with the maximum amount of DMSO (0.25%) and considered as 100% viability.
    (Only for Reference)
Animal Research:[2]
- Collapse
  • Animal Models: FVB/N or nude NMRI female mice bearing NT2 and MDA-MB-231 tumors
  • Formulation: DMSO
  • Dosages: 100 mg/kg
  • Administration: i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 63 mg/mL (199.14 mM)
Ethanol 34 mg/mL warmed (107.47 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+50% PEG 300+ddH2O
For best results, use promptly after mixing.
30mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 316.35
Formula

C18H20O5

CAS No. 117048-59-6
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How to make solution for in vivo IP injection?

  • Answer:

    We've tested some vehicles for S7783 Combretastatin A4, and found it can be dissolved in 5% DMSO+50% PEG 300+ddH2O at 30mg/ml clearly. When prepare the solution, please dissolve the compound in DMSO clearly first. The add PEG, after they mixed well, then dilute with water.

Microtubule Associated Signaling Pathway Map

Related Microtubule Associated Products

Tags: buy Combretastatin A4 | Combretastatin A4 supplier | purchase Combretastatin A4 | Combretastatin A4 cost | Combretastatin A4 manufacturer | order Combretastatin A4 | Combretastatin A4 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID